Does insulin-like growth factor influence prognosis ten months after myocardial infarction?

Yücel Yılmaz,Namık Kemal Eryol,Mustafa Duran,Fatih Tanriverdi,Mustafa Altay,Eyüp Özkan

doi:10.21601/ortadogutipdergisi.506160

Abstract

Background: We investigated the levels of insulin-like growth factor-1 (IGF-1) in acute myocardial infarction (AMI) patients, and we determined whether a decrease in IGF-1 could influence long-term prognosis.Methods: In total, 65 patients who were admitted to our hospital for AMI and 25 healthy controls were included in this study. Fasting blood samples were obtained from all patients immediately after AMI and 10 months later to determine their IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) levels. Fasting blood samples were obtained from the control group. The patients were also evaluated for cardiac events 10 months after AMI.Results: The IGF-1 levels were higher in the AMI patients than in the healthy controls (p=0.002); after 10 months, both the IGFBP-3 and IGF-1 levels were higher. No differences were found in cardiac event occurrence between patients with low and high IGF-1 and IGFBP-3 levels (for both the baseline and 10-month values).Conclusions: The serum total IGF-1 and IGFBP-3 levels were higher in the AMI patients compared to the control patients; however, there was no correlation between the IGF-1 and IGFBP-3 levels and cardiac events during the 10-month period after AMI. Additional studies are needed to clarify the time required for IGF-1 and IGFBP-3 level normalization after AMI, and to determine the effects of IGF-1 and IGFBP-3 on the long-term prognosis of patients after AMI.

Highlights

Insulin-like growth factor-1 (IGF-1) plays a pivotal role in the regulation of cellular growth, proliferation, and differentiation, and in the inhibition of apoptosis and necrosis
Patients with uncontrolled hypertension, diabetes mellitus, acromegaly, history of coronary artery disease (CAD) or heart failure, thyroid deficiency, hepatic dysfunction, Killip score of 3-4, aortic or mitral valve dysfunction, cardiomyopathy, history of acute pericarditis or myocarditis, acute or chronic renal failure, systemic infection, musculoskeletal disease, or cancer, and those who were on medications that would affect serum insulin-like growth factor-1 (IGF-1)/insulin-like growth factor binding protein-3 (IGFBP-3) levels were excluded from the study
In the acute myocardial infarction (AMI) patients, the IGF-1 levels were higher whereas the systolic blood pressure (SBP) was lower compared with the control group (p=0.002 and 0.03, respectively)

Summary

Introduction

Insulin-like growth factor-1 (IGF-1) plays a pivotal role in the regulation of cellular growth, proliferation, and differentiation, and in the inhibition of apoptosis and necrosis. We investigated the levels of insulin-like growth factor-1 (IGF-1) in acute myocardial infarction (AMI) patients, and we determined whether a decrease in IGF-1 could influence long-term prognosis. Fasting blood samples were obtained from all patients immediately after AMI and 10 months later to determine their IGF-1 and insulin-like growth factor binding protein-3 (IGFBP-3) levels. Conclusions: The serum total IGF-1 and IGFBP-3 levels were higher in the AMI patients compared to the control patients; there was no correlation between the IGF-1 and IGFBP-3 levels and cardiac events during the 10-month period after AMI. Additional studies are needed to clarify the time required for IGF-1 and IGFBP-3 level normalization after AMI, and to determine the effects of IGF-1 and IGFBP-3 on the long-term prognosis of patients after AMI.

Methods

Results

Discussion

Conclusion